Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin cardioprotection in sickle cell disease
RBR-6m2hb8hPhase 2Not yet recruiting
- Sponsor
- Hemocentro Unicamp
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dapagliflozin in sickle cell disease (SCD) (2 arms), sponsored by Hemocentro Unicamp. Primary endpoint: Primary endpoint not reported. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on RBR-6m2hb8h.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-6m2hb8h.